ZALTRAP® (Aflibercept) Approved In The EU For Patients With Previously Treated Metastatic Colorectal Cancer
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimenSanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Health | Statistics